<DOC>
	<DOCNO>NCT00002847</DOCNO>
	<brief_summary>RATIONALE : Biological therapy use different way stimulate immune system try stop cancer cell grow . Combining interferon alfa interleukin-2 may kill tumor cell . PURPOSE : Phase II trial study effectiveness interferon alfa interleukin-2 treating patient metastatic kidney cancer .</brief_summary>
	<brief_title>Interferon Alfa Interleukin-2 Treating Patients With Metastatic Kidney Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Evaluate response disease-free survival patient metastatic renal cell carcinoma treat subcutaneous interleukin-2 interferon alfa . - Assess toxicity regimen . OUTLINE : Patients undergo nephrectomy diseased kidney make bulk tumor burden . All patient receive subcutaneous interferon alfa day 1 interleukin-2 day 3-5 week 1 , follow reduced dos interferon alfa interleukin-2 day 1 , 3 , 5 week 2-6 . Patients assessed response approximately 2 month initiate therapy . Patients stable respond disease undergo second course ; continue respond may receive additional therapy provide toxicity limit . Patients follow survival . PROJECTED ACCRUAL : 14 patient enter .</detailed_description>
	<mesh_term>Kidney Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Aldesleukin</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interleukin-2</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically prove renal cell cancer metastatic No great 50 % estimate hepatic replacement tumor CT MRI No symptomatic involvement CNS major nerve Measurable disease require Ineligible treatment lowdose interleukin2 another CMC protocol PATIENT CHARACTERISTICS : Age : 18 Performance status : Karnofsky 50 % 100 % Life expectancy : More 3 month Hematopoietic : No coagulopathy ( i.e. , platelet count le 80,000/mm3 ) Hepatic : AST ALT great 5 time normal Renal : Creatinine le 4.0 mg/dL Cardiovascular : No symptomatic angina No untreated coronary artery disease No refractory arrhythmia No abnormal leave ventricular function Pulmonary : No dyspnea minimal exertion Other : No site ongoing bleed No systemic infection No HIV antibody No HBsAg No requirement steroids No psychiatric disease precludes inform consent protocol treatment No second malignancy except : Basal cell skin carcinoma Carcinoma situ cervix Not pregnant nursing Effective contraception require fertile woman PRIOR CONCURRENT THERAPY : Biologic therapy No prior interleukin2 Chemotherapy Not specify Endocrine therapy Not specify Radiotherapy Not specify Surgery Not specify Other At least 28 day since prior treatment renal cell cancer</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2003</verification_date>
	<keyword>stage IV renal cell cancer</keyword>
	<keyword>recurrent renal cell cancer</keyword>
</DOC>